Fisher & Paykel Healthcare Corporation Limited (FSPKF)
USD 16.35
(-25.78%)
USD 16.35
(-25.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 1.74 Billion NZD | 10.67% |
| 2023 | 1.58 Billion NZD | -3.28% |
| 2022 | 1.64 Billion NZD | -15.7% |
| 2021 | 1.94 Billion NZD | 52.99% |
| 2020 | 1.27 Billion NZD | 18.78% |
| 2019 | 1.07 Billion AUD | 11.16% |
| 2018 | 964.5 Million AUD | 10.93% |
| 2017 | 869.5 Million AUD | 6.23% |
| 2016 | 818.49 Million AUD | 27.09% |
| 2015 | 644.01 Million AUD | 13.26% |
| 2014 | 568.6 Million AUD | 12.1% |
| 2013 | 507.25 Million AUD | 8.68% |
| 2012 | 466.72 Million AUD | -0.2% |
| 2011 | 467.68 Million AUD | -1.49% |
| 2010 | 474.75 Million AUD | -2.22% |
| 2009 | 485.51 Million AUD | 40.34% |
| 2008 | 345.96 Million AUD | -0.94% |
| 2007 | 349.24 Million AUD | 20.62% |
| 2006 | 289.54 Million AUD | 20.08% |
| 2005 | 241.13 Million AUD | 12.23% |
| 2004 | 214.86 Million AUD | 3.09% |
| 2003 | 208.42 Million AUD | -2.27% |
| 2002 | 213.25 Million AUD | 10.58% |
| 2001 | 192.84 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 469.55 Million NZD | 0.0% |
| 2024 Q2 | 815.8 Million NZD | 103.01% |
| 2024 Q3 | 469.55 Million NZD | -42.44% |
| 2024 FY | 1.75 Billion NZD | 10.67% |
| 2024 Q1 | 401.85 Million NZD | -55.06% |
| 2023 Q1 | 345.3 Million NZD | -54.73% |
| 2023 Q2 | 694.5 Million NZD | 101.13% |
| 2023 Q4 | 894.1 Million NZD | 100.81% |
| 2023 FY | 1.58 Billion NZD | -3.28% |
| 2023 Q3 | 445.25 Million NZD | -35.89% |
| 2022 Q4 | 762.8 Million NZD | 95.16% |
| 2022 Q1 | 450 Million NZD | -56.63% |
| 2022 FY | 1.64 Billion NZD | -15.7% |
| 2022 Q2 | 879.6 Million NZD | 95.47% |
| 2022 Q3 | 390.85 Million NZD | -55.57% |
| 2021 Q1 | 455.1 Million NZD | -34.9% |
| 2021 Q3 | 530.5 Million NZD | -41.74% |
| 2021 Q4 | 1.03 Billion NZD | 95.59% |
| 2021 FY | 1.94 Billion NZD | 52.99% |
| 2021 Q2 | 910.6 Million NZD | 100.09% |
| 2020 Q1 | 285.45 Million NZD | 2.11% |
| 2020 Q4 | 699.1 Million NZD | 101.82% |
| 2020 Q3 | 346.4 Million NZD | -39.68% |
| 2020 FY | 1.27 Billion NZD | 18.78% |
| 2020 Q2 | 574.3 Million NZD | 101.19% |
| 2019 FY | 1.07 Billion AUD | 11.16% |
| 2019 Q4 | 279.55 Million NZD | 0.0% |
| 2019 Q3 | 279.55 Million NZD | 9.35% |
| 2019 Q2 | 255.65 Million NZD | 0.0% |
| 2019 Q1 | 255.65 Million NZD | -2.12% |
| 2018 Q3 | 261.2 Million NZD | 13.96% |
| 2018 FY | 964.5 Million AUD | 10.93% |
| 2018 Q1 | 229.2 Million NZD | -2.3% |
| 2018 Q2 | 229.2 Million NZD | 0.0% |
| 2018 Q4 | 261.2 Million NZD | 0.0% |
| 2017 Q1 | 212.6 Million NZD | -2.14% |
| 2017 FY | 869.5 Million AUD | 6.23% |
| 2017 Q4 | 234.6 Million NZD | 0.0% |
| 2017 Q3 | 234.6 Million NZD | 10.35% |
| 2017 Q2 | 212.6 Million NZD | 0.0% |
| 2016 Q4 | 217.26 Million NZD | 0.0% |
| 2016 Q3 | 217.26 Million NZD | 14.06% |
| 2016 Q2 | 190.48 Million NZD | 0.0% |
| 2016 Q1 | 190.48 Million NZD | 7.34% |
| 2016 FY | 818.49 Million AUD | 27.09% |
| 2015 Q1 | 158.72 Million NZD | -0.65% |
| 2015 Q3 | 177.45 Million NZD | 11.8% |
| 2015 Q4 | 177.45 Million NZD | 0.0% |
| 2015 FY | 644.01 Million AUD | 13.26% |
| 2015 Q2 | 158.72 Million NZD | 0.0% |
| 2014 Q1 | 151.95 Million NZD | 5.05% |
| 2014 FY | 568.6 Million AUD | 12.1% |
| 2014 Q3 | 159.76 Million NZD | 5.14% |
| 2014 Q2 | 151.95 Million NZD | 0.0% |
| 2014 Q4 | 159.76 Million NZD | 0.0% |
| 2013 Q4 | 144.65 Million NZD | 0.0% |
| 2013 Q3 | 144.65 Million NZD | 0.0% |
| 2013 FY | 507.25 Million AUD | 8.68% |
| 2012 FY | 466.72 Million AUD | -0.2% |
| 2011 FY | 467.68 Million AUD | -1.49% |
| 2010 FY | 474.75 Million AUD | -2.22% |
| 2009 FY | 485.51 Million AUD | 40.34% |
| 2008 FY | 345.96 Million AUD | -0.94% |
| 2007 FY | 349.24 Million AUD | 20.62% |
| 2006 FY | 289.54 Million AUD | 20.08% |
| 2005 FY | 241.13 Million AUD | 12.23% |
| 2004 FY | 214.86 Million AUD | 3.09% |
| 2003 FY | 208.42 Million AUD | -2.27% |
| 2002 FY | 213.25 Million AUD | 10.58% |
| 2001 FY | 192.84 Million AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Medical Technologies Inc. | 3.19 Million USD | -54507.996% |
| Ansell Limited | 1.61 Billion USD | -7.627% |
| Ansell Limited | 1.61 Billion USD | -7.627% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 184.64 Million USD | -843.853% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 135.05 Thousand USD | -1290337.229% |
| Psykey, Inc. | 419.29 Thousand USD | -415546.114% |
| ConvaTec Group Plc | 2.19 Billion USD | 20.566% |
| ConvaTec Group Plc | 2.14 Billion USD | 18.652% |
| Encision Inc. | 6.58 Million USD | -26362.667% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 1.82 Million USD | -95399.815% |
| LifePoint, Inc. | -18.5 Thousand USD | 9420640.541% |
| Medite Cancer Diagnostics, Inc. | 6.81 Million USD | -25480.508% |
| Paradigm Medical Industries, Inc. | 772 Thousand USD | -225651.295% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 986.22 Thousand USD | -176615.135% |
| Reflect Scientific, Inc. | 1.08 Million USD | -161247.363% |
| SmileDirectClub, Inc. | 470.74 Million USD | -270.223% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.87 Billion USD | 6.882% |
| SheerVision, Inc. | 3.49 Million USD | -49702.724% |
| United Health Products, Inc. | - USD | -Infinity% |
| Vasamed, Inc. | 1.38 Million USD | -125616.479% |
| Wearable Health Solutions, Inc. | 745.09 Thousand USD | -233803.687% |
| Yubo International Biotech Limited | 104.28 Thousand USD | -1671121.58% |